FATE
Fate Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$144.19M
P/E Ratio
—
EPS
$-1.15
Beta
2.24
52W High
$1.94
52W Low
$0.91
50-Day MA
$1.29
200-Day MA
$1.18
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | $6.65M |
| Gross Profit (TTM) | $-85.25M |
| EBITDA | $-133.70M |
| Operating Margin | -2456.00% |
| Return on Equity | -51.80% |
| Return on Assets | -24.10% |
| Revenue/Share (TTM) | $0.06 |
| Book Value | $1.80 |
| Price-to-Book | 0.73 |
| Price-to-Sales (TTM) | 21.70 |
| EV/Revenue | 3.816 |
| EV/EBITDA | -2.59 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -26.40% |
| Shares Outstanding | $116.28M |
| Float | $101.62M |
| % Insiders | 1.03% |
| % Institutions | 78.72% |
Historical Volatility
HV 10-Day
49.37%
HV 20-Day
55.88%
HV 30-Day
61.58%
HV 60-Day
71.62%
HV Rank
7.1%
Volatility is currently contracting
Analyst Ratings
Consensus ($4.94 target)
1
Strong Buy5
Buy6
HoldData last updated: 4/30/2026